Forastiere A A
Johns Hopkins University, School of Medicine, Department of Oncology, Johns Hopkins Oncology Center, Baltimore, USA.
Acta Otorhinolaryngol Belg. 1999;53(3):253-7.
The taxoids docetaxel and paclitaxel entered into clinical trials in the 1980s. Paclitaxel has dominated clinical investigations in the United States while docetaxel gained a foothold early in Europe. Now both agents are under intensive study in both countries. The Eastern Cooperative Oncology Group (ECOG) conducted a series of paclitaxel trials in patients with recurrent or metastatic squamous cell head and neck. The current study directly compares paclitaxel + cisplatin to cisplatin + 5-FU. Similarly, an international trial is in progress directly comparing docetaxel-based chemotherapy to cisplatin + 5-FU. For patients with locally advanced disease, phase I-II trials evaluating various doses and schedules of paclitaxel or docetaxel administered concurrently with radiotherapy are in progress or recently reported in preliminary form. No one regimen is clearly preferred. The results of selected studies and trials in progress in the United States are reviewed.
紫杉烷类药物多西他赛和紫杉醇于20世纪80年代进入临床试验阶段。紫杉醇在美国主导了临床研究，而多西他赛则在欧洲早期就站稳了脚跟。现在这两种药物在两国都受到深入研究。东部肿瘤协作组（ECOG）对复发性或转移性头颈部鳞状细胞癌患者进行了一系列紫杉醇试验。当前的研究直接比较了紫杉醇+顺铂与顺铂+5-氟尿嘧啶的疗效。同样，一项国际试验正在进行中，直接比较以多西他赛为基础的化疗与顺铂+5-氟尿嘧啶的疗效。对于局部晚期疾病患者，评估紫杉醇或多西他赛与放疗同时使用的不同剂量和给药方案的I-II期试验正在进行中，或者最近已以初步形式报道。尚无一种方案明显更受青睐。本文综述了美国部分已开展研究及正在进行的试验结果。
